Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4162MR)

This product GTTS-WQ4162MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4162MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9915MR IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA KB-003
GTTS-WQ9357MR IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA INCMGA-00012
GTTS-WQ4487MR IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-931699
GTTS-WQ15730MR IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA VIR-7831
GTTS-WQ14113MR IVTScrip™ mRNA-Anti-NGF, aNGF75(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA aNGF75
GTTS-WQ13052MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PEG-IFN-SA
GTTS-WQ3565MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 1112623
GTTS-WQ9831MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA JTX-2011
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW